Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Table 1 Characteristics of patients in this study

Characteristic	Total (n=133) N(%)	NLR			PLR			MLR
Characteristic	Total (n=133) N(%)	<5 (n=103, 77.4%)	>5 (n=30, 22.6%)	p	<135 (n=53, 39.8%)	>135 (n=80, 60.2%)	p	<0.31 (n=64, 48.1%)	>0.31 (n=69, 51.9%)	p
Sex				0.845			0.106			0.113
Female	38(28.6%)	29	9		11	27		24	14
Male	95(71.4%)	74	21		42	53		40	55
Age	64.6±11.0	64.1±10.7	66.2±11.1	0.342	63.8±11.5	65.1±10.4	0.538	63.2±10.8	65.9±11.4	0.144
BMI	23.4±3.4	23.3±3.4	23.6±3.4	0.744	23.2±3.7	23.5±3.2	0.657	23.8±3.5	23.0±3.3	0.179
Smoke				0.311			0.052			0.223
Yes	90(67.7%)	72	18		41	49		40	50
No	43(32.3%)	31	12		12	31		24	19
Cancer type				0.213			0.753			0.063
UTUC	80(60.2%)	59	21		31	49		29	51
BC	53(39.8%)	44	9		22	31		35	18
pT stage				0.916			0.366			0.512
pT2	75(56.4%)	62	13		30	45		45	30
pT3	44(33.1%)	32	12		18	26		15	29
pT4	14(10.5%)	9	5		5	9		4	10
Lymph node involvement				0.079			0.858			0.071
pN0	119(89.5%)	92	27		49	70		55	59
pN+	14(10.5%)	11	3		4	10		9	10
With chemotherapy				0.244			0.382			0.213
Yes	108(81.2%)	79	29		43	65		45	63
No	25(18.8%)	20	5		10	15		19	6
Adverse events				0.482			0.108			0.077
No	87(65.4%)	69	18		39	48		37	50
Yes	46(34.6%)	34	12		14	32		27	19

ISSN: 1471-2407